Shah A, Mwamburi M

Modeling the budget impact of availability of biosimilars of infliximab and adalimumab in rheumatoid arthritis using published claim-based algorithm data in the US.

Leave a reply

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> 

required